Wang Xiangyi, Yu Zhaojin, Liu Wensi, Tang Haichao, Yi Dongxu, Wei Minjie
Department of Pharmacology, School of Pharmacy, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Am J Cancer Res. 2021 Jun 15;11(6):2401-2416. eCollection 2021.
Tumor immunotherapy has now become one of the most potential therapy for those intractable cancer diseases. The antigens on the cancer cell surfaces are the keys for the immune system to recognize and eliminate them. As reported, the immunogenicity of the tumor antigens could be determined by the binding between the key epitope peptides and MHC molecules. In recent years, the approaches to anticipate the peptides from the candidate epitopes have gradually changed into more efficient methods. Including the improved conventional methods, more diverse methods were coming into view. Here we review the anticipated methods of the tumor associated epitopes that specifically bind with major histocompatibility complex (MHC) class I molecules, and the recent advances and applications of those epitope prediction methods.
肿瘤免疫疗法现已成为治疗那些难治性癌症疾病最具潜力的疗法之一。癌细胞表面的抗原是免疫系统识别和清除它们的关键。据报道，肿瘤抗原的免疫原性可由关键表位肽与MHC分子之间的结合来决定。近年来，从候选表位预测肽的方法已逐渐转变为更有效的方法。包括改进的传统方法在内，更多样化的方法不断涌现。在此，我们综述了与主要组织相容性复合体（MHC）I类分子特异性结合的肿瘤相关表位的预测方法，以及这些表位预测方法的最新进展和应用。
